Dr. Reddy’s Laboratories (RDY) to Release Quarterly Earnings on Thursday

Dr. Reddy’s Laboratories (NYSE:RDY) is projected to release its Q3 25/26 results before the market opens on Thursday, January 22nd. Analysts expect Dr. Reddy’s Laboratories to post earnings of $0.16 per share and revenue of $963.8440 million for the quarter. Investors may visit the the company’s upcoming Q3 25/26 earning results page for the latest details on the call scheduled for Wednesday, January 21, 2026 at 9:00 AM ET.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Friday, October 24th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.01. The company had revenue of $993.72 million during the quarter, compared to analyst estimates of $944.26 million. Dr. Reddy’s Laboratories had a return on equity of 17.13% and a net margin of 17.14%. On average, analysts expect Dr. Reddy’s Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Dr. Reddy’s Laboratories Stock Performance

Shares of NYSE:RDY opened at $13.29 on Thursday. The company has a market capitalization of $11.09 billion, a price-to-earnings ratio of 16.40, a P/E/G ratio of 6.25 and a beta of 0.37. The firm’s 50 day simple moving average is $13.89 and its 200 day simple moving average is $14.18. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.85 and a quick ratio of 1.35. Dr. Reddy’s Laboratories has a fifty-two week low of $12.26 and a fifty-two week high of $16.17.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Dr. Reddy’s Laboratories in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Dr. Reddy’s Laboratories currently has a consensus rating of “Buy” and a consensus price target of $16.90.

Hedge Funds Weigh In On Dr. Reddy’s Laboratories

Several institutional investors and hedge funds have recently modified their holdings of RDY. Vise Technologies Inc. boosted its position in Dr. Reddy’s Laboratories by 6.0% during the third quarter. Vise Technologies Inc. now owns 20,074 shares of the company’s stock valued at $281,000 after purchasing an additional 1,128 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Dr. Reddy’s Laboratories by 71.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock worth $47,000 after purchasing an additional 1,294 shares in the last quarter. Aquatic Capital Management LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 2.3% in the 3rd quarter. Aquatic Capital Management LLC now owns 68,168 shares of the company’s stock valued at $953,000 after buying an additional 1,536 shares during the last quarter. Van ECK Associates Corp grew its stake in shares of Dr. Reddy’s Laboratories by 25.2% in the third quarter. Van ECK Associates Corp now owns 9,355 shares of the company’s stock valued at $131,000 after buying an additional 1,881 shares in the last quarter. Finally, Modern Wealth Management LLC increased its holdings in Dr. Reddy’s Laboratories by 12.6% during the second quarter. Modern Wealth Management LLC now owns 17,785 shares of the company’s stock worth $267,000 after buying an additional 1,996 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.